prednisolone has been researched along with Hemangioma Thrombocytopenia Syndrome in 11 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 7.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Sirolimus was added; he became transfusion independent with no further bleeding and reduction in tumor size." | 5.48 | Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus. ( Cashell, J; Helm, K; Smink, GM; Xavier, F, 2018) |
| "Sirolimus was effective and safe for the treatment of progressive KHE." | 5.46 | Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. ( Chen, S; Ji, Y; Li, K; Li, Y; Liu, X; Lu, G; Tang, X; Wang, C; Wang, Q; Wu, H; Xia, C; Xiang, B; Xu, T; Xu, Z; Yang, G; Yang, K; Yao, W, 2017) |
| "Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon." | 3.88 | ( Dillingham, CS; Givner, LB; McLean, TW; Rinker, EK; Russell, TB, 2018) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 3.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Sirolimus was added; he became transfusion independent with no further bleeding and reduction in tumor size." | 1.48 | Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus. ( Cashell, J; Helm, K; Smink, GM; Xavier, F, 2018) |
| "Sirolimus was effective and safe for the treatment of progressive KHE." | 1.46 | Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. ( Chen, S; Ji, Y; Li, K; Li, Y; Liu, X; Lu, G; Tang, X; Wang, C; Wang, Q; Wu, H; Xia, C; Xiang, B; Xu, T; Xu, Z; Yang, G; Yang, K; Yao, W, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, Y | 2 |
| Chen, S | 2 |
| Zhou, J | 1 |
| Yang, K | 2 |
| Zhang, X | 1 |
| Xiang, B | 2 |
| Qiu, T | 1 |
| Gong, X | 1 |
| Zhang, Z | 1 |
| Lan, Y | 1 |
| Hu, F | 1 |
| Kong, F | 1 |
| Qiu, Q | 1 |
| Zhang, Y | 1 |
| Li, K | 1 |
| Xu, Z | 1 |
| Yao, W | 1 |
| Lu, G | 1 |
| Liu, X | 1 |
| Xia, C | 1 |
| Wang, Q | 1 |
| Li, Y | 1 |
| Wang, C | 1 |
| Yang, G | 1 |
| Tang, X | 1 |
| Xu, T | 1 |
| Wu, H | 1 |
| Mizutani, K | 1 |
| Umaoka, A | 1 |
| Tsuda, K | 1 |
| Kakeda, M | 1 |
| Habe, K | 1 |
| Yamanaka, K | 1 |
| Suyama, M | 1 |
| Mizutani, H | 1 |
| Russell, TB | 1 |
| Rinker, EK | 1 |
| Dillingham, CS | 1 |
| Givner, LB | 1 |
| McLean, TW | 1 |
| Gültekin, ND | 1 |
| Yilmaz, FH | 1 |
| Altunhan, H | 1 |
| Findik, S | 1 |
| Tokgöz, H | 1 |
| Çalişkan, Ü | 1 |
| Cashell, J | 1 |
| Smink, GM | 1 |
| Helm, K | 1 |
| Xavier, F | 1 |
| Fichel, F | 1 |
| Eschard, C | 1 |
| Zachar, D | 1 |
| Munzer, M | 1 |
| Bernard, P | 1 |
| Grange, F | 1 |
| Downing, A | 1 |
| Chauhan, A | 1 |
| Lotterman, C | 1 |
| Craver, R | 1 |
| Warrier, R | 1 |
| Uno, T | 1 |
| Ito, S | 1 |
| Nakazawa, A | 1 |
| Miyazaki, O | 1 |
| Mori, T | 1 |
| Terashima, K | 1 |
| Tamai, N | 1 |
| Hashii, Y | 1 |
| Osuga, K | 1 |
| Chihara, T | 1 |
| Morii, E | 1 |
| Aozasa, K | 1 |
| Yoshikawa, H | 1 |
| Jahnel, J | 1 |
| Lackner, H | 1 |
| Reiterer, F | 1 |
| Urlesberger, B | 1 |
| Urban, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma: a Randomized Controlled Trial[NCT05324384] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-05 | Recruiting | ||
| Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome[NCT03188068] | Phase 2 | 30 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Different Doses of Sirolimus for Kaposiform Hemangioendothelioma: a Randomized Clinical Trial[NCT04775173] | Phase 2 | 79 participants (Actual) | Interventional | 2021-02-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for prednisolone and Hemangioma Thrombocytopenia Syndrome
| Article | Year |
|---|---|
Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.
Topics: Hemangioendothelioma; Humans; Infant; Kasabach-Merritt Syndrome; Prednisolone; Sarcoma, Kaposi; Siro | 2022 |
Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.
Topics: Hemangioendothelioma; Humans; Infant; Kasabach-Merritt Syndrome; Prednisolone; Sarcoma, Kaposi; Siro | 2022 |
Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.
Topics: Hemangioendothelioma; Humans; Infant; Kasabach-Merritt Syndrome; Prednisolone; Sarcoma, Kaposi; Siro | 2022 |
Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.
Topics: Hemangioendothelioma; Humans; Infant; Kasabach-Merritt Syndrome; Prednisolone; Sarcoma, Kaposi; Siro | 2022 |
10 other studies available for prednisolone and Hemangioma Thrombocytopenia Syndrome
| Article | Year |
|---|---|
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2017 |
Successful combination therapy of propranolol and prednisolone for a case with congenital Kasabach-Merritt syndrome.
Topics: Glucocorticoids; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Male; Prednisolone; Propranolol | 2017 |
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Therapy, | 2018 |
Coexistence of Kasabach-Merritt Syndrome and placental chorioangioma in a premature infant.
Topics: Anti-Inflammatory Agents; Comorbidity; Fatal Outcome; Female; Hemangioma; Humans; Infant, Newborn; K | 2018 |
Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Child; Hemangioendothel | 2018 |
[Kaposiform haemangioendothelioma associated with B-cell acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Combined Modality Therapy | 2013 |
Giant vascular malformation with thrombocytopenia in a newborn.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Arm; Female; Hemangioendothelioma; Huma | 2013 |
Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neoplasm; Everolimus; Hemang | 2015 |
Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon.
Topics: Antineoplastic Agents, Hormonal; Deltoid Muscle; Diagnosis, Differential; Disseminated Intravascular | 2010 |
Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2012 |